MICHAEL JAMES OVERMAN to Ipilimumab
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Ipilimumab.
Connection Strength
0.975
-
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 03 10; 36(8):773-779.
Score: 0.425
-
Nivolumab?plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 10; 33(10):1052-1060.
Score: 0.144
-
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 01 10; 40(2):161-170.
Score: 0.138
-
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer. 2020 06; 19(2):73-81.
Score: 0.123
-
Immunotherapy in colorectal cancer with mismatch repair deficiency. Clin Adv Hematol Oncol. 2019 May; 17(5):265-267.
Score: 0.116
-
Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461.
Score: 0.029